Premium
A Real‐World Evidence Framework for Optimizing Dosing in All Patients With COVID‐19
Author(s) -
Peck Richard W.,
Weiner Daniel,
Cook Jack,
Robert Powell J.
Publication year - 2020
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1922
Subject(s) - dosing , covid-19 , intensive care medicine , medicine , pandemic , medline , medical emergency , pharmacology , disease , virology , infectious disease (medical specialty) , biology , outbreak , biochemistry
Potential treatments for coronavirus disease 2019 (COVID‐19) are being investigated at unprecedented speed, and successful treatments will rapidly be used in tens or hundreds of thousands of patients. To ensure safe and effective use in all those patents it is essential also to develop, at unprecedented speed, a means to provide frequently updated, optimal dosing information for all patient subgroups. Success will require immediate collaboration between drug developers, academics, and regulators.